Blood Sugar (Glucose) ControlNCT07705191
Effect of SugarLock® Peanut Skin Extract on Postprandial Blood Glucose Control
A study testing Peanut skin extract, White kidney bean extract and Water in people with Blood Sugar (Glucose) Control and Postprandial Glucose, run by TCI Co., Ltd. at 1 site in Taiwan.
Trial summary
The objective of this study is to investigate the effects of pre-meal supplementation with SugarLock® peanut skin extract and white kidney bean extract on reducing or delaying postprandial blood glucose elevation and glycemic fluctuations, and to evaluate their potential as nutritional supplements for postprandial… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Blood Sugar (Glucose) Control, Postprandial Glucose
- What is being tested?
- Peanut skin extract, White kidney bean extract and Water
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteTaiwan
- Study dates
- 9 Jul 2026to 31 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older;
- Fasting blood glucose level < 100 mg/dL;
- Individuals without type 1 or type 2 diabetes.
Who cannot join
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
- Individuals with chronic gastrointestinal diseases (such as irritable bowel syndrome [IBS], inflammatory bowel disease [IBD], chronic diarrhea, celiac disease, short bowel syndrome, ulcers, colorectal cancer, etc.), a history of epilepsy or seizures, psychiatric disorders, malignant tumors, endocrine disorders, liver or kidney disease, or other major organic diseases;
- Individuals with a history of gastrointestinal surgery or organ transplantation;
- Individuals who have taken medications or supplements affecting blood glucose or insulin within the past three months;
- Individuals allergic to peanuts or white kidney beans;
- Full-time employees in the same department as the principal investigator, and students directly taught by the principal investigator during the current semester.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
Chang Jung Christian University
Tainan, 711301
Fang-Pei Chen, Ph.D., +886-06-2785123 ext. 3310, fpchen@mail.cjcu.edu.tw
Fang-Pei Chen, Ph.D.
About this study
Official title: Assessing the Impact of SugarLock® Peanut Skin Extract on Postprandial Blood Glucose Control
The objective of this study is to investigate the effects of pre-meal supplementation with SugarLock® peanut skin extract and white kidney bean extract on reducing or delaying postprandial blood glucose elevation and glycemic fluctuations, and to evaluate their potential as nutritional supplements for postprandial glycemic management.
Read the detailed description
This study is a single-center, randomized 2×3 crossover human trial designed to evaluate the effect of SugarLock® peanut skin extract on postprandial glycemic regulation. Healthy adults aged over 18 years with fasting blood glucose below 100 mg/dL and without type 1 or type 2 diabetes will be enrolled. Each participant will complete three test visits, with at least a 48-hour washout interval, while wearing a continuous glucose monitoring system (CGM). On each test day, after fasting for at least 10 hours, participants will consume either two peanut skin extract capsules, two white kidney bean extract capsules, or water only 15 minutes before eating white rice containing 50 g of carbohydrates. Postprandial glucose responses will then be continuously monitored for 3 hours to assess the effects on blood glucose elevation and glycemic fluctuation.
- Being tested
- Peanut skin extract, White kidney bean extract, Water
- Keywords
- SugarLock, peanut skin extract, postprandial glycemic regulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peanut skin extractDietary supplement
Also called SugarLock®
consume two peanut skin extract capsules (200 mg/capsule) with 150 mL water
White kidney bean extractDietary supplement
consume two White kidney bean extract capsules (250 mg/capsule) with 150 mL water
WaterDietary supplement
consume 150 mL water
| Study group | Role | What they receive |
|---|---|---|
| Blank control | Placebo comparator | consume 150 mL water 15 minutes before eating white rice containing 50 g of carbohydrates Receives: Dietary Supplement: Water |
| SugarLock® peanut skin extract | Experimental | consume two SugarLock® peanut skin extract capsules (200 mg/capsule) with 150 mL water 15 minutes before eating white rice containing 50 g of carbohydrates Receives: Dietary Supplement: Peanut skin extract |
| White kidney bean extract | Active comparator | consume two White kidney bean extract capsules (250 mg/capsule) with 150 mL water 15 minutes before eating white rice containing 50 g of carbohydrates Receives: Dietary Supplement: White kidney bean extract |
What is being measured
The primary outcome is the main question the study is designed to answer.
Interstitial fluid glucose level (mg/dL)
Postprandial glucose responses will then be continuously monitored by continuous glucose monitoring system (CGM) for 3 hours
Measured: at 3 hours after eating white rice
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2026
- Study start9 Jul 2026
- Primary completion30 Sep 2026 (estimated)
- Study completion31 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood Sugar (Glucose) ControlStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- TCI Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Fang-Pei Chen, Principal investigator, Chang Jung Christian University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07705191
- Sponsor's protocol ID
- A-ER-115-167
- Status last verified
- Jul 2026
- First submitted
- 9 Jul 2026
- Last updated
- 15 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing the Impact of SugarLock® Peanut Skin Extract on Postprandial Blood Glucose Control
- ClinicalTrials.gov ID
- NCT07705191
- Acronym / sponsor ID
- A-ER-115-167
- Keywords
- SugarLock, peanut skin extract, postprandial glycemic regulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- TCI Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 9 Jul 2026 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 31 Oct 2026 (estimated)
- First posted
- 15 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to investigate the effects of pre-meal supplementation with SugarLock® peanut skin extract and white kidney bean extract on reducing or delaying postprandial blood glucose elevation and glycemic fluctuations, and to evaluate their potential as nutritional supplements for postprandial glycemic management.
Detailed description
This study is a single-center, randomized 2×3 crossover human trial designed to evaluate the effect of SugarLock® peanut skin extract on postprandial glycemic regulation. Healthy adults aged over 18 years with fasting blood glucose below 100 mg/dL and without type 1 or type 2 diabetes will be enrolled. Each participant will complete three test visits, with at least a 48-hour washout interval, while wearing a continuous glucose monitoring system (CGM). On each test day, after fasting for at least 10 hours, participants will consume either two peanut skin extract capsules, two white kidney bean extract capsules, or water only 15 minutes before eating white rice containing 50 g of carbohydrates. Postprandial glucose responses will then be continuously monitored for 3 hours to assess the effects on blood glucose elevation and glycemic fluctuation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Blank control | Placebo comparator | Dietary Supplement: Waterconsume 150 mL water 15 minutes before eating white rice containing 50 g of carbohydrates |
| SugarLock® peanut skin extract | Experimental | Dietary Supplement: Peanut skin extractconsume two SugarLock® peanut skin extract capsules (200 mg/capsule) with 150 mL water 15 minutes before eating white rice containing 50 g of carbohydrates |
| White kidney bean extract | Active comparator | Dietary Supplement: White kidney bean extractconsume two White kidney bean extract capsules (250 mg/capsule) with 150 mL water 15 minutes before eating white rice containing 50 g of carbohydrates |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 18 years or older;
- Fasting blood glucose level < 100 mg/dL;
- Individuals without type 1 or type 2 diabetes.
Key exclusion criteria (6 listed)
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
- Individuals with chronic gastrointestinal diseases (such as irritable bowel syndrome [IBS], inflammatory bowel disease [IBD], chronic diarrhea, celiac disease, short bowel syndrome, ulcers, colorectal cancer, etc.), a history of epilepsy or seizures, psychiatric disorders, malignant tumors, endocrine disorders, liver or kidney disease, or other major organic diseases;
- Individuals with a history of gastrointestinal surgery or organ transplantation;
- Individuals who have taken medications or supplements affecting blood glucose or insulin within the past three months;
- Individuals allergic to peanuts or white kidney beans;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peanut skin extractAlso: SugarLock®consume two peanut skin extract capsules (200 mg/capsule) with 150 mL water | Dietary supplement | SugarLock® peanut skin extract |
| White kidney bean extractconsume two White kidney bean extract capsules (250 mg/capsule) with 150 mL water | Dietary supplement | White kidney bean extract |
| Waterconsume 150 mL water | Dietary supplement | Blank control |
Primary outcome
Interstitial fluid glucose level (mg/dL)
Time frame: at 3 hours after eating white rice
Postprandial glucose responses will then be continuously monitored by continuous glucose monitoring system (CGM) for 3 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
Related trials for Blood Sugar (Glucose) Control
Not yet recruiting
A Nurse-Led Digital Coaching Program to Improve Blood Sugar Control in Adults With Type 2 Diabetes
Type 2 Diabetes Mellitus
RecruitingPhase 3
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Type 2 Diabetes
Recruiting
RIGHTEST iFree 2 CGM System for Glycemic Control in Adults With Diabetes Mellitus
Diabetes (DM)
Not yet recruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
Type 2 Diabetes Mellitus
Not yet recruitingObservational study
Maternal Glucose, Cortisol, and Neonatal Outcomes With and Without GDM
Gestational Diabetes Mellitus in Pregnancy, Diet- Controlled
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Fang-Pei Chen principal investigator
Chang Jung Christian University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Peanut skin extract, White kidney bean extract and Water in people with Blood Sugar (Glucose) Control and Postprandial Glucose, run by TCI Co., Ltd. at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fang-Pei Chen, Ph.D. (+886-06-2785123 ext. 3310, fpchen@mail.cjcu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interstitial fluid glucose level (mg/dL) (time frame: at 3 hours after eating white rice). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.